Fosfomycin susceptibility in carbapenem-resistant enterobacteriaceae from Germany

Journal of Clinical Microbiology

Volumn 52, Issue 6, 2014, Pages 1893-1897

  Kaase, Martin ^a   Szabados, Florian ^b   Anders, Agnes ^a   Gatermann, Sören G ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Laborarztpraxis Osnabrück ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CARBAPENEMASE; ERTAPENEM; FOSFOMYCIN; GIM CARBAPENEMASE; IMIPENEM; KPC CARBAPENEMASE; MEROPENEM; METALLO BETA LACTAMASE; NDM CARBAPENEMASE; OXA 48 CARBAPENEMASE; OXACILLIN; UNCLASSIFIED DRUG; VIM CARBAPENEMASE; CARBAPENEM DERIVATIVE;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; DISK DIFFUSION; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTION; EPSILOMETER TEST; ESCHERICHIA COLI; GERMANY; HUMAN; KLEBSIELLA PNEUMONIAE; KPC-2 GENE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; OXA-162 GENE; OXA-48 GENE; PRIORITY JOURNAL; VIM-1 GENE; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; ENTEROBACTERIACEAE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

BETA-LACTAM RESISTANCE; CARBAPENEMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FOSFOMYCIN; GERMANY; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84901649592     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03484-13     Document Type: Article

References (31)

1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. 2012. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin. Microbiol. Rev. 25:682-707. http://dx.doi.org/10.1128/CMR.05035-11.
2. Queenan AM, Bush K. 2007. Carbapenemases: the versatile betalactamases. Clin. Microbiol. Rev. 20:440-458, table of contents. http://dx.doi.org/10.1128/ CMR.00001-07.
3. Keating GM. 2013. Fosfomycin trometamol: a review of its use as a singledose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs 73:1951- 1966. http://dx.doi.org/10.1007/s40265-013-0143-y.
4. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H. 2013. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase- producing Gram-negative bacteria. Int. J. Antimicrob. Agents 43:52-59. http://dx.doi.org/10.1016/j.ijantimicag.2013.09.010.
5. Michalopoulos AS, Livaditis IG, Gougoutas V. 2011. The revival of fosfomycin. Int. J. Infect. Dis. 15:e732-e739. http://dx.doi.org/10.1016/j.ijid. 2011.07.007.
6. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. 2012. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J. Antimicrob. Chemother. 67: 255-268. http://dx.doi.org/10.1093/jac/dkr466.
7. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Pitout JDD, Gregson DB, Poirel L, McClure JA, Le P, Church DL. 2005. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J. Clin. Microbiol. 43:3129-3135. http://dx.doi.org/10. 1128/JCM.43.7.3129-3135.2005. (Pubitemid 40981312)
9. Pasteran F, Mendez T, Guerriero L, Rapoport M, Corso A. 2009. Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae. J. Clin. Microbiol. 47:1631-1639. http://dx.doi.org/10.1128/ JCM.00130-09.
10. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. 2001. Novel carbapenemhydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45:1151-1161. http://dx.doi.org/10. 1128/AAC.45.4.1151-1161.2001. (Pubitemid 32230996)
11. Juan C, Beceiro A, Guti?rrez O, Albert? S, Garau M, P?rez JL, Bou G, Oliver A. 2008. Characterization of the new metallo-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. Antimicrob. Agents Chemother. 52:3589-3596. http://dx.doi.org/10.1128/AAC.00465- 08.
12. Kaase M, Szabados F, Pfennigwerth N, Anders A, Geis G, Pranada AB, Rler S, Lang U, Gatermann SG. 2014. Description of the metallo- lactamase GIM-1 in Acinetobacter pittii. J. Antimicrob. Chemother. 69:81-84. http://dx.doi.org/10. 1093/jac/dkt325.
13. Poirel L, H?ritier C, Tol?n V, Nordmann P. 2004. Emergence of oxacillinase- mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48:15-22. http://dx.doi.org/10.1128/AAC.48.1.15- 22.2004. (Pubitemid 38040171)
14. Marchiaro P, Mussi MA, Ballerini V, Pasteran F, Viale AM, Vila AJ, Limansky AS. 2005. Sensitive EDTA-based microbiological assays for detection of metallo-lactamases in nonfermentative gram-negative bacteria. J. Clin. Microbiol. 43:5648-5652. http://dx.doi.org/10.1128/JCM.43.11.5648-5652.2005. (Pubitemid 41612343)
15. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. 2004. Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase. Antimicrob. Agents Chemother. 48:4654-4661. http://dx.doi.org/10.1128/AAC.48.12.4654-4661.2004. (Pubitemid 39577668)
16. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-8th ed. CLSI document M7-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Lu CL, Liu CY, Huang YT, Liao CH, Teng LJ, Turnidge JD, Hsueh PR. 2011. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob. Agents Chemother. 55:4295-4301. http://dx.doi.org/10.1128/AAC.00349-11.
18. Pasteran F, Lucero C, Rapoport M, Guerriero L, Barreiro I, Albornoz E, Veliz O, Corso A. 2012. Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae. J. Infect. Dev. Ctries. 6:452-456.
19. U.S. Food and Drug Administration. 2007. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ucm080564.htm.
20. Bland JM, Altman DG. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310. (Pubitemid 16134762)
21. Landis JR, Koch GG. 1977. The measurement of observer agreement for categorical data. Biometrics 33:159-174. http://dx.doi.org/10.2307/2529310. (Pubitemid 8054849)
22. Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB, Jacobs MR, Bonomo RA. 2010. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob. Agents Chemother. 54:526-529. http://dx.doi.org/10. 1128/AAC.01235-09.
23. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. 2010. Antimicrobial susceptibility of multidrug- resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents 35:240-243. http://dx.doi.org/10.1016/j.ijantimicag. 2009.10.019.
24. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. 2011. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int. J. Antimicrob. Agents 37:415-419. http://dx.doi.org/10.1016/j.ijantimicag.2011.01.012.
25. Hsu MS, Liao CH, Liu CY, Yang CJ, Huang YT, Hsueh PR. 2011. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents. Int. J. Antimicrob. Agents 37:276-278. http://dx.doi.org/10.1016/j.ijantimicag.2010.12.003.
26. Alexander BT, Marschall J, Tibbetts RJ, Neuner EA, Dunne WM, Jr, Ritchie DJ. 2012. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin. Ther. 34:1314-1323. http://dx.doi.org/10.1016/j.clinthera.2012.05.002.
27. Neuner EA, Sekeres J, Hall GS, van Duin D. 2012. Experience with fosfomycin for treatment of urinary tract infections due to multidrugresistant organisms. Antimicrob. Agents Chemother. 56:5744-5748. http://dx.doi.org/10. 1128/AAC.00402-12.
28. Ho PL, Chan J, Lo WU, Lai EL, Cheung YY, Lau TC, Chow KH. 2013. Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates. J. Med. Microbiol. 62:1707-1713. http://dx.doi.org/10.1099/jmm.0.062653-0.
29. Cattoir V. 2010. Chloramphenicol, fosfomycin, fusidic acid, and polymyxins, p 357-372. In Courvalin P, LeClercq R, Rice LB (ed), Antibiogram. ASM Press, Washington, DC.
30. Souli M, Galani I, Boukovalas S, Gourgoulis MG, Chryssouli Z, Kanellakopoulou K, Panagea T, Giamarellou H. 2011. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob. Agents Chemother. 55:2395-2397. http://dx.doi.org/10.1128/AAC.01086-10.
31. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. 2003. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. 47:2850-2858. http://dx.doi.org/10.1128/AAC.47.9. 2850-2858.2003. (Pubitemid 37040258)